Skip to main content
. 2022 Aug 22;30(1):137–151. doi: 10.1038/s41418-022-01051-7

Fig. 6. SOCS2-SH2 domain interacted with N-terminal domain of SLC7A11 to reduce radioresistance.

Fig. 6

A Schematic representation of three flag-fused SOCS2 constructs containing amino acids 1–40, 40–156 and 156–198. B Co-immunoprecipitation assay of SLC7A11 and different SOCS2 domains in the whole cell lysates of irradiated SK-Hep-1 and HepG2 cells. C Ubiquitination of SLC7A11 in irradiated SK-Hep-1 and HepG2 cells with or without ΔSH2 manipulation (ΔSH2, SH2 domain truncation mutant of SOCS2). D Schematic representation of three flag-fused SLC7A11 constructs containing amino acids 1–43, 43–470 and 470–501. E Co-immunoprecipitation assay of SOCS2 and different SLC7A11 domains in the whole cell lysates of irradiated SK-Hep-1 and HepG2 cells. F SLC7A11 polyubiquitination was detected by anti-Ub immunoblotting in 4 Gy irradiated SK-Hep-1 and HepG2 cells with or without ΔNTD manipulation (ΔNTD, NTD domain truncation mutant of SOCS2). G, H Dose responses of survival fractions of SK-Hep-1 and HepG2 cells transfected with SOCS2-ΔSH2 or SOCS2-WT plasmid. *P < 0.05, **P < 0.01 and ***P < 0.001 between indicated groups.